Product Description: Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active?colony-stimulating factor-1 receptor (CSF-1R)?inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively[1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration?in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research[1][2].
Applications: COVID-19-immunoregulation
Formula: C27H35N5O2
References: [1]Mancuso R, et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice.Brain. 2019 Oct 1;142(10):3243-3264./[2]Genovese MC, et al. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.J Rheumatol. 2015 Oct;42(10):1752-60.
CAS Number: 1142363-52-7
Molecular Weight: 461.60
Compound Purity: 98.78
Research Area: Inflammation/Immunology; Neurological Disease; Cancer
Solubility: DMSO : 16.67 mg/mL (ultrasonic)
Target: c-Fms
English
Deutsch
